Novavax, Sanofi Sign Multibillion-Dollar Deal for COVID-19 and Flu Vaccines

May 10, 2024, 07:34 AM

Novavax and Sanofi have entered into a multibillion-dollar licensing agreement to co-commercialize a COVID-19 vaccine and to develop novel combination vaccines for COVID-19 and influenza. The deal also includes Sanofi taking an equity stake in Novavax. This collaboration aims to enhance vaccine availability and efficacy against these respiratory diseases.